Table 2. Association between stromal HIF-1α expression and clinicopathological phenotype and hormone receptor status in endometrial cancer patients.
| Variable | Categories | Stromal HIF-1α protein expression | ||
|---|---|---|---|---|
| High % (N) | Low % (N) | P* | ||
| Histological type & grade | EEC Grade 1–2 | 24 (113) | 76 (365) | 0.001 |
| N = 691 | EEC Grade 3 | 37 (37) | 63 (63) | |
| NEEC | 37 (42) | 63 (71) | ||
| Myometrial infiltration | < 50% | 27 (116) | 73 (317) | 0.5 |
| N = 688 | > 50% | 29 (75) | 71 (180) | |
| Lymph node metastasis | No | 29 (144) | 71 (360) | 0.03 |
| N = 558 | Yes | 43 (23) | 57 (31) | |
| FIGO stage (2009) | I/II | 26 (153) | 74 (438) | 0.007 |
| N = 691 | III/IV | 39 (39) | 61 (61) | |
| ERα protein expression | High | 23 (121) | 77 (405) | < 0.001 |
| N = 684 | Low | 43 (68) | 57 (90) | |
| PR protein expression | High | 23 (128) | 77 (417) | < 0.001 |
| N = 683 | Low | 44 (61) | 56 (77) | |
Abbreviations: HIF, hypoxia-inducible factor; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endometrial cancer; ER, estrogen receptor; PR; progesterone receptor; N, number of patients assessed for stromal HIF-1α protein expression.
*
Chi-square test.